S-1: Shuttle Pharma files S-1 for 625k share resale

Shuttle Pharmaceuticals registered 625,156 shares for resale tied to a November 2025 pre‑funded warrant, adding a potential stock overhang while providing no proceeds to the company.

Summary

• Registers 625,156 shares of common stock issuable upon exercise of a pre-funded warrant from a November 3, 2025 private placement; the warrant has a nominal $0.001 exercise price and no expiration.
• No proceeds will be received by the company from any resale; the selling stockholder bears selling commissions while the company pays registration expenses.
• Private placement closed November 4, 2025 for approximately $2.5 million gross proceeds; WestPark Capital earned a 4% placement fee and expense reimbursement.
• Common stock trades on Nasdaq Capital Market (SHPH); last reported sale price was $1.92 on November 17, 2025.
• Selling stockholder: Alternative Investment Capital Inc.; table shows 780,877 shares beneficially owned prior to the offering, 625,156 shares offered, and 1,406,033 shares beneficially owned after the offering (47.1%) based on 1,603,285 shares outstanding as of November 17, 2025 (subject to a 4.99% exercise blocker).
• Auditor Forvis Mazars, LLP included a going concern explanatory paragraph in the 2024 audit opinion incorporated by reference.
• Business update highlights include ongoing Phase II trial of Ropidoxuridine (brain cancer RT sensitizer) initiated in October 2024 with FDA-recommended randomized dose optimization and completed IRB approvals.
• Contemplates an asset purchase under a binding term sheet dated October 20, 2025 with 1542770 BC Ltd. (Molecule), with risks around execution, timing, and integration noted.

Sentiment

Score: 4

Explanation: Resale creates a sizable stock overhang without delivering new proceeds; going concern uncertainty persists despite recent financings. Operational progress in the Phase II program offers some offset.

Positives

• Recent gross financing of approximately $2.5 million (November 2025) enhances near-term liquidity.
• Pre-funded warrant structure (nominal $0.001 exercise price, no expiration) provides flexibility to the investor and can simplify future equity conversions.
• Operational progress: Phase II clinical study of Ropidoxuridine commenced in October 2024 with FDA input; drug supply and CRO/site infrastructure in place.
• Efficient placement economics: 4% placement agent fee (below many small-cap biotech ranges of ~6–8%).

Negatives

• Resale registration creates an overhang: 625,156 shares may be sold by the investor, potentially pressuring the stock price.
• Company receives no proceeds from resales despite ongoing capital needs.
• Going concern uncertainty highlighted by the independent auditor for 2024.
• High shareholder concentration risk indicated by the selling stockholder’s stated post-offering beneficial ownership and separate pre-funded warrants (subject to a 4.99% blocker).
• History of dilutive financings, including January 2023 convertible notes and October 2024 senior secured convertible notes/warrants, signals potential for further dilution.

Risks

• Potential pressure on the stock price from substantial sales by the selling stockholder of registered shares.
• Execution, timing, and integration risks related to the contemplated asset acquisition with 1542770 BC Ltd. (Molecule), including the possibility of not receiving intended benefits.
• Going concern uncertainty noted by Forvis Mazars, LLP regarding the company’s ability to continue operations without additional financing.
• Exposure to volatility, potential dilution from future equity or debt issuance, early-stage development risk for product candidates, and IP protection risks (as noted in forward-looking statements).

Future Outlook

Plans include obtaining effectiveness of this resale registration within 45 days of November 3, 2025 (or 75 days if reviewed), continuing the ongoing Phase II trial of Ropidoxuridine with FDA-recommended design changes, pursuing clinical validation of radiation biomarkers and potential commercialization pathways, and working toward execution and closing of the contemplated Molecule asset acquisition subject to definitive agreements and conditions.

Management Comments

• Believes its product candidates can make cancer treatments safer and more reliable at greater scale by enhancing outcomes from radiation therapy.
• Reports operational readiness for the Phase II brain cancer study, including FDA protocol modifications, IRB approvals, site initiations, and drug supply.
• Intends to proceed with clinical validation of radiation biomarkers and evaluate commercialization potential of Ropidoxuridine as a radiation sensitizer.

Industry Context

Micro-cap biotechs commonly use pre-funded warrants to raise capital efficiently while managing investor ownership caps; registering these shares for resale is standard and often creates a near-term overhang. In oncology, the niche of radiation therapy sensitizers is competitive but under-served, with interest focused on agents that can safely amplify radiotherapy outcomes.

Comparison to Industry Standards

• Financing structure: Pre-funded warrants with a nominal exercise price and 4.99% blocker are common in small-cap biotech; the 4% placement fee is modest compared with typical 6–8% fees for similar micro-cap transactions.
• Share overhang: A resale registration of 625k shares is meaningful relative to 1.6m shares outstanding, implying higher-than-average overhang risk versus larger-cap peers where registered resales represent a smaller proportion.
• Oncology radiosensitizer field: Companies like Nanobiotix (NBTX) pursue radiotherapy enhancers; Shuttle’s program is earlier stage (Phase II) and capital constrained versus better-capitalized peers, indicating higher financing and execution risk.

Related Party Transactions

• In October 2024 senior secured convertible note and warrant offering, the CEO purchased $250,000 of notes and warrants.

Stakeholder Impact

• Shareholders: Potential near-term selling pressure from registered resales; dilution and concentration risks persist due to pre-funded warrants and historical convertible financings.
• Employees and clinical collaborators: Recent financing supports ongoing Phase II operations and trial momentum.
• Suppliers/CROs: Registration and recent financings help fund obligations to manufacturers and CRO partners.
• Creditors: Going concern language underscores reliance on continued access to capital markets.

Next Steps

• Seek SEC effectiveness of the S-1 within 45 days of November 3, 2025 (or 75 days if reviewed).
• Maintain prospectus effectiveness until Rule 144 resales are permitted without volume/manner-of-sale limits or all registered shares are sold.
• Continue enrollment and execution of the Phase II Ropidoxuridine trial with the FDA-recommended randomized dose optimization step.
• Advance toward definitive agreements and closing for the contemplated Molecule asset acquisition, subject to conditions.
• Pursue clinical validation of radiation biomarkers and assess commercialization potential for Ropidoxuridine as a radiation sensitizer.

Key Dates

Recommendation

The resale registration introduces significant share overhang relative to a 1.6 million share base and provides no cash to the company, while the auditor’s going concern note and history of dilutive financings elevate risk. Operational progress is noted, but on balance, the risk/reward implied by this filing skews negative in the near term.

Keywords

Shuttle Pharmaceuticals, SHPH, S-1, resale registration, pre-funded warrant, radiation sensitizer, Ropidoxuridine, Phase II clinical trial, WestPark Capital, Alternative Investment Capital Inc., Nasdaq Capital Market, biotech financing, dilution